KRAS and colorectal carcinoma: Based on in vitro experiments showing that KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells, it has been suggested that mutant KRAS CRC patients might benefit more from receiving first-line oxaliplatin-based regimens [17].